Fumiko Ladd Chino, Radiation Oncologist at MD Anderson Cancer Center, shared an article by Avital M. Miller et al on X:
“Toxicity in phase III oncology clinical trials is often incompletely reported and is frequently minimized in its interpretation.
Only 1/3 reported Grade 1 to 2 toxicities and toxicity-minimizing language was used in 46% (subjectively downplay the harm of drugs).”
Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials
Authors: Avital M. Miller et al
